Anika Therapeutics, Inc.

Total Valuation

Anika Therapeutics, Inc. carries a market capitalization of 287.73M, placing it among publicly traded companies globally. Its enterprise value stands at 181.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Anika Therapeutics, Inc. currently has 13.31M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 1.68, and the price-to-book ratio stands at 1.42.

Enterprise Valuation

On an enterprise value basis, Anika Therapeutics, Inc. trades at an EV/EBITDA multiple of 354.49 and an EV/FCF ratio of 15.93. The EV/Sales ratio of 1.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.84 provides insight into valuation relative to core operating earnings.

Financial Position

Anika Therapeutics, Inc. maintains a current ratio of 4.48, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Anika Therapeutics, Inc. has paid 208,000.00 in income taxes, reflecting an effective tax rate of 2.10.

Stock Price Statistics

Anika Therapeutics, Inc.'s stock has gained approximately 143.48811% over the past 52 weeks. The 50-day moving average sits at 16.37, while the 200-day moving average is 13.09.

Income Statement

Over the trailing twelve months, Anika Therapeutics, Inc. generated 120.65M in revenue and converted that into -3.78M in net income, yielding earnings per share of -0.22. EBITDA reached 512,000.00, while operating income came in at -5.12M.

Balance Sheet

Anika Therapeutics, Inc. holds 38.41M in cash and equivalents against 25.25M in total debt, resulting in a net debt position of -38.41M. Total book value stands at 137.28M, with working capital of 77.04M providing operational flexibility.

Cash Flow

Anika Therapeutics, Inc. produced 5.98M in operating cash flow over the past twelve months. After subtracting -5.41M in capital expenditures, free cash flow totaled 562,000.00 - equivalent to 0.04 per share.

Margins

Anika Therapeutics, Inc. operates with a gross margin of 62.16, reflecting its pricing power and cost economics. The operating margin of -4.24 and net profit margin of -3.14 provide insight into operational efficiency.

Dividends & Yields

Scores

Anika Therapeutics, Inc. posts an Altman Z-Score of 4.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.